

## Summary of risk management plan for Tigecycline Panpharma 50 mg powder for solution for infusion (Tigecycline)

This is a summary of the risk management plan (RMP) for Tigecycline Panpharma 50 mg powder for solution for infusion. The RMP details important risks of Tigecycline Panpharma 50 mg powder for solution for infusion, how these risks can be minimised, and how more information will be obtained about Tigecycline Panpharma 50 mg powder for solution for infusion for injection risks and uncertainties (missing information).

Tigecycline Panpharma 50 mg powder for solution for infusion summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Tigecycline Panpharma 50 mg powder for solution for infusion should be used.

### **I. The medicine and what it is used for**

Tigecycline Panpharma 50 mg powder for solution for infusion is authorised in adults and in children from the age of eight years for the treatment of complicated skin and soft tissue infections, excluding diabetic foot infections; and for the treatment of complicated intra-abdominal infections. Tigecycline Panpharma should be used only in situations where other alternative antibiotics are not suitable.

It contains tigecycline as the active substance and it is given by intravenous route (infusion).

### **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of Tigecycline Panpharma 50 mg powder for solution for infusion, together with measures to minimise such risks and the proposed studies for learning more about Tigecycline Panpharma 50 mg powder for solution for infusion's risks, are outlined below.

Measures to minimise the risks identified for medicinal products are:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Tigecycline Panpharma 50 mg powder for solution for infusion is not yet available, it is listed under 'missing information' below.

### **II.A List of important risks and missing information**

Important risks of Tigecycline Panpharma 50 mg powder for solution for infusion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered.

Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Tigecycline Panpharma 50 mg powder for solution for infusion. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation.

Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the longterm use of the medicine).

<b>List of important risks and missing information</b>	
Important identified risks	None
Important potential risks	None
Missing information	None

### **II.B Summary of important risks**

The safety information in the proposed Product Information is aligned to the reference medicinal product.

### **II.C Post-authorisation development plan**

#### II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Tigecycline Panpharma 50 mg powder for solution for infusion.

#### II.C.2 Other studies in post-authorisation development plan

There are no studies required for Tigecycline Panpharma 50 mg powder for solution for infusion.